Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACHL NASDAQ:HUMA NASDAQ:IMMP NASDAQ:PBYI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACHLAchilles Therapeutics$1.48$1.48$0.63▼$1.51$60.83M1.25744,051 shsN/AHUMAHumacyte$1.47-2.0%$2.00$1.15▼$6.77$237.56M1.873.36 million shs1.17 million shsIMMPPrima BioMed$1.64-1.2%$1.70$1.32▼$2.71$243.67M1.7186,220 shs32,038 shsPBYIPuma Biotechnology$4.47-0.7%$4.19$2.32▼$6.07$226.67M1.38665,169 shs377,459 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACHLAchilles Therapeutics0.00%0.00%0.00%0.00%+111.40%HUMAHumacyte+1.35%+2.74%-16.43%-36.71%-73.64%IMMPPrima BioMed+1.84%+2.47%-2.35%-4.60%-35.91%PBYIPuma Biotechnology-0.88%-11.94%-7.60%+34.33%+80.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACHLAchilles Therapeutics$1.48$1.48$0.63▼$1.51$60.83M1.25744,051 shsN/AHUMAHumacyte$1.47-2.0%$2.00$1.15▼$6.77$237.56M1.873.36 million shs1.17 million shsIMMPPrima BioMed$1.64-1.2%$1.70$1.32▼$2.71$243.67M1.7186,220 shs32,038 shsPBYIPuma Biotechnology$4.47-0.7%$4.19$2.32▼$6.07$226.67M1.38665,169 shs377,459 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACHLAchilles Therapeutics0.00%0.00%0.00%0.00%+111.40%HUMAHumacyte+1.35%+2.74%-16.43%-36.71%-73.64%IMMPPrima BioMed+1.84%+2.47%-2.35%-4.60%-35.91%PBYIPuma Biotechnology-0.88%-11.94%-7.60%+34.33%+80.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACHLAchilles Therapeutics 0.00N/AN/AN/AHUMAHumacyte 2.88Moderate Buy$9.75563.27% UpsideIMMPPrima BioMed 3.00Buy$7.00326.83% UpsidePBYIPuma Biotechnology 3.00Buy$7.0056.60% UpsideCurrent Analyst Ratings BreakdownLatest ACHL, HUMA, PBYI, and IMMP Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/27/2025HUMAHumacyteBarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$3.508/27/2025HUMAHumacyteBarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$3.508/12/2025HUMAHumacyteTD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$5.00 ➝ $3.508/12/2025HUMAHumacyteHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$4.00 ➝ $3.008/11/2025HUMAHumacyteD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$25.007/23/2025HUMAHumacyteD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$25.007/9/2025HUMAHumacyteD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$25.00(Data available from 9/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACHLAchilles TherapeuticsN/AN/AN/AN/A$3.49 per shareN/AHUMAHumacyte$1.57M148.28N/AN/A($0.41) per share-3.59IMMPPrima BioMed$6.69M35.98N/AN/A$0.63 per share2.60PBYIPuma Biotechnology$230.50M0.98$0.85 per share5.28$1.88 per share2.38Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACHLAchilles Therapeutics-$69.67M-$1.65N/AN/AN/AN/A-54.45%-47.68%N/AHUMAHumacyte-$148.70M-$0.45N/AN/AN/AN/AN/A-78.26%11/14/2025 (Estimated)IMMPPrima BioMed-$39.78MN/A0.00N/AN/AN/AN/AN/AN/APBYIPuma Biotechnology$30.28M$0.984.5611.76N/A20.38%53.15%23.51%11/6/2025 (Estimated)Latest ACHL, HUMA, PBYI, and IMMP EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/11/2025Q2 2025HUMAHumacyte-$0.15-$0.24-$0.09-$0.24$0.94 million$0.30 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthACHLAchilles TherapeuticsN/AN/AN/AN/AN/AHUMAHumacyteN/AN/AN/AN/AN/AIMMPPrima BioMedN/AN/AN/AN/AN/APBYIPuma BiotechnologyN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACHLAchilles TherapeuticsN/A6.046.04HUMAHumacyte2.972.451.93IMMPPrima BioMedN/A11.69N/APBYIPuma Biotechnology0.101.731.62Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACHLAchilles Therapeutics56.38%HUMAHumacyte44.71%IMMPPrima BioMed2.32%PBYIPuma Biotechnology61.29%Insider OwnershipCompanyInsider OwnershipACHLAchilles Therapeutics5.38%HUMAHumacyte5.10%IMMPPrima BioMed3.07%PBYIPuma Biotechnology23.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACHLAchilles Therapeutics25041.10 million38.89 millionNot OptionableHUMAHumacyte150158.37 million150.30 millionOptionableIMMPPrima BioMed2,021146.79 million142.28 millionOptionablePBYIPuma Biotechnology20050.37 million38.64 millionOptionableACHL, HUMA, PBYI, and IMMP HeadlinesRecent News About These Companies79,101 Shares in Puma Biotechnology, Inc. $PBYI Bought by Nuveen LLCSeptember 8, 2025 | marketbeat.comPuma Biotechnology (NASDAQ:PBYI) Rating Increased to Strong-Buy at Wall Street ZenSeptember 8, 2025 | marketbeat.comAre Strong Financial Prospects The Force That Is Driving The Momentum In Puma Biotechnology, Inc.'s NASDAQ:PBYI) Stock?September 4, 2025 | finance.yahoo.comPuma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)September 4, 2025 | businesswire.comPuma Biotechnology to Present at the H.C. Wainwright 27th Annual Global Investment ConferenceSeptember 2, 2025 | businesswire.comAmerican Century Companies Inc. Has $3.40 Million Holdings in Puma Biotechnology, Inc. $PBYISeptember 2, 2025 | marketbeat.comPuma Biotech (PBYI) May Find a Bottom Soon, Here's Why You Should Buy the Stock NowSeptember 1, 2025 | zacks.comShould Value Investors Buy Puma Biotechnology (PBYI) Stock?August 28, 2025 | zacks.comVirtus Advisers LLC Makes New Investment in Puma Biotechnology, Inc. $PBYIAugust 27, 2025 | marketbeat.comPuma Biotechnology (NASDAQ:PBYI) Upgraded by Wall Street Zen to Buy RatingAugust 18, 2025 | marketbeat.comConnor Clark & Lunn Investment Management Ltd. Boosts Stock Holdings in Puma Biotechnology, Inc. (NASDAQ:PBYI)August 16, 2025 | marketbeat.comAdditional Considerations Required While Assessing Puma Biotechnology's (NASDAQ:PBYI) Strong EarningsAugust 15, 2025 | finance.yahoo.comPuma Biotechnology Reports Strong Q2 2025 EarningsAugust 13, 2025 | msn.comBarclays Maintains a Sell Rating on Puma Biotechnology (PBYI) With a $2 PTAugust 12, 2025 | msn.comShould Value Investors Buy Puma Biotechnology (PBYI) Stock?August 12, 2025 | zacks.comPuma Biotechnology, Inc. (PBYI) Soars to 52-Week High, Time to Cash Out?August 12, 2025 | zacks.comResults: Puma Biotechnology, Inc. Beat Earnings Expectations And Analysts Now Have New ForecastsAugust 10, 2025 | finance.yahoo.comPuma Biotechnology, Inc. (NASDAQ:PBYI) Q2 2025 Earnings Call TranscriptAugust 9, 2025 | msn.comPBYI's Q2 Earnings Beat Estimates, Nerlynx Sales Drive RevenuesAugust 8, 2025 | zacks.comPuma (PBYI) Q2 Revenue Rises 11%August 8, 2025 | fool.comPuma Biotechnology, Inc. (PBYI) Q2 2025 Earnings Call TranscriptAugust 7, 2025 | seekingalpha.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeACHL, HUMA, PBYI, and IMMP Company DescriptionsAchilles Therapeutics NASDAQ:ACHLAchilles Therapeutics plc, a biopharmaceutical company, develops precision T cell therapies to treat solid tumors. Its platform identifies mutations formed early in the development of cancer. The company offers PELEUS, a proprietary AI-powered bioinformatics platform, used to identify clonal neoantigens in a patient. It also develops CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in Phase I/IIa clinical trial for use in the treatment of metastatic or recurrent melanoma. The company was formerly known as Achilles TX Limited and changed its name to Achilles Therapeutics Plc in February 2021. Achilles Therapeutics Plc was founded in 2016 and is headquartered in London, the United Kingdom.Humacyte NASDAQ:HUMA$1.47 -0.03 (-2.00%) Closing price 04:00 PM EasternExtended Trading$1.48 +0.01 (+0.68%) As of 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection. It is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; pediatric heart surgery; and coronary artery bypass grafting, as well as for the delivery of cellular therapy, including pancreatic islet cell transplantation to treat Type 1 diabetes. The company was founded in 2004 and is headquartered in Durham, North Carolina.Prima BioMed NASDAQ:IMMP$1.64 -0.02 (-1.20%) Closing price 04:00 PM EasternExtended Trading$1.66 +0.02 (+1.22%) As of 06:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Immutep Limited, a clinical-stage biotechnology company, engages in developing novel LAG-3 Immunotherapy for cancer and autoimmune diseases. The company is involved in advancing therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), a cell surface molecule that plays a vital role in regulating the immune system. Its LAG-3 immunotherapies are designed to harness and strengthen the power of patients' immune systems to fight cancer and autoimmune disease. Its lead product candidate is eftilagimod alpha (efti or IMP321) for the treatment of different types of cancers. The trials that efi is being evaluated in include TACTI-002, a Phase II clinical trial for the treatment of head and neck squamous cell carcinoma (HNSCC) and non-small cell lung cancer (NSCLC); TACTI-003, a Phase IIb clinical trial to treat HNSCC; and INSIGHT-003, a Phase I clinical trial for the treatment of NSCLC, as well as INSIGHT-005, a Phase I/IIa clinical trial to treat solid tumors. In addition, it offers IMP761, an agonist of lymphocyte activation gene 3 for autoimmune disease; IMP701, an antagonist antibody that acts to stimulate T cell proliferation in cancer patients; and IMP731, a depleting antibody that removes T cells involved in autoimmunity. The company has collaboration agreements with GlaxoSmithKline, Novartis, CYTLIMIC Inc., Merck & Co., Inc., Institute of Clinical Cancer Research, Merck KGaA, and EOC Pharma. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. The company was incorporated in 1987 and is headquartered in Sydney, Australia.Puma Biotechnology NASDAQ:PBYI$4.47 -0.03 (-0.67%) Closing price 04:00 PM EasternExtended Trading$4.47 0.00 (0.00%) As of 06:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. It also develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. The company sells its products through specialty pharmacy and distributor networks. It has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds; and Takeda Pharmaceutical Company Limited for the research, development, and commercialization of alisertib, as well as sub-license agreements with Specialised Therapeutics Asia Pte Ltd., Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Post Onum Deal: Is CrowdStrike Ready to Rebound After 16% Drop? Chewy’s September Pullback: Is It Your Time to Buy? It’s Time to Buy the Dip in Kroger Stock Price Is Coupang the Next MercadoLibre? A Playbook for Global Dominance Vanguard’s VUG ETF: The Ultimate Growth ETF for Your Portfolio Tesla's U.S. Market Is At An 8-Year Low... How Bad Could It Get? Not Just NVDA: 3 Semiconductor Stocks Struggling This Quarter Broadcom Gets Big Upgrades: How High Analysts See Shares Going Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
